2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult
PAPER

2090 IDH1- and IDH2-mutated MDS are clinically and molecularly distinct entities with risk-stratum-dependent outcomes

Ian Bouligny, M.D., Guillermo Montalban-Bravo, MD2, Alex Bataller, MD, PhD3, Kelly Sharon Chien, MD4, Alexandre Bazinet, MD, MSc5, Danielle Hammond, MD6, Mahesh Swaminathan, MD7, Wei Ying Jen, BM BCh, FRCPath8, Thura Htut, MD, MRCP, FRCPath9, Charan Thej Reddy Vegivinti, MD, MBBS10, Farhad Ravandi, MD11, Elias Jabbour, MD12, Nicholas Short, MD13, Ghayas C. Issa, MD14, Gautam Borthakur, MD15, Naval Daver, MD16, Abhishek Maiti, MBBS17, Eitan Kugler, MD PhD18, Hannah Goulart, MD19, Jennifer Marvin-Peek, MD20, Musa Yilmaz, MD21, Naveen Pemmaraju, MD22, Tapan Kadia I, MD23, Sanam Loghavi, MD24, Courtney DiNardo, MD, MSCE25, Guillermo Garcia-Manero, MD26
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
24 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
25 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
26 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background

IDH1 and IDH2 mutations occur in 5–12% of myelodysplastic syndromes (MDS) and are targetable with IDH inhibitors. Prior studies conducted before the availability of IDH inhibitors and venetoclax reported IDH mutations as adverse or neutral prognostic markers. Whether the prognostic impact of IDH mutations has changed in the modern treatment era has not been systematically evaluated.

 

Methods

This was a real-world cohort study of 1020 patients with MDS (n=855), MDS/MPN (n=46), and CMML (n=119) at MD Anderson Cancer Center (2014–2026), drawn from CURE MDS, a database with EHR linkage and manual verification of all records. IDH status was confirmed in 940 patients via NGS (IDH1, n=65; IDH2, n=115; dual IDH1/IDH2, n=6; wild-type [WT], n=754). The primary endpoint was OS from diagnosis, compared across isoforms using Kaplan-Meier estimation and log-rank tests. Multivariable Cox regression adjusted for age, ECOG, and disease type, stratified by IPSS-R risk. Consensus clustering was performed separately by isoform on binary mutation and cytogenetic features using Ward's linkage with 1000 bootstrap iterations.

 

Results

In the overall cohort, median age was 70 years (range, 21-94), and 940 (92%) had baseline NGS. IDH1 hotspot distribution included R132C (53%), R132H (34%), and R132G (10%); the predominant IDH2 mutation was R140Q (91%). IDH1 mutations were less frequent in CMML vs non-CMML (2% vs 8%; p=0.02), and enriched in MDS/MPN (16% vs 7%; p=0.02).

Compared to WT, IDH1 patients had lower WBC (2.5 vs. 3.8; p<0.001), lower ANC (0.8 vs. 1.9; p<0.001), higher hemoglobin (10.5 vs. 9.3; p=0.003), higher blasts (6% vs. 3%; p=0.001), lower transfusion dependence (35% vs. 52%; p=0.019), and less therapy-related disease (5% vs. 22%; p<0.001). IDH2 patients had higher platelets (132 vs. 104; p=0.014), higher blasts (5% vs. 3%; p<0.001), lower transfusion dependence (33% vs. 52%; p<0.001), and less therapy-related disease (14% vs. 22%; p=0.049).

Co-mutation analysis revealed isoform-specific molecular landscapes. Both isoforms were enriched for SRSF2 (IDH141%, IDH2 51% vs. WT 18%; p<0.001) and depleted for TP53 (IDH1 9%, IDH2 11% vs. 28%; p<0.005) and TET2 (IDH1 7%, IDH2 15% vs. 28%; p<0.01) mutations. IDH2 was uniquely enriched for ASXL1 (52% vs. 29%; p<0.001), KRAS (10% vs 4%; p=0.044), and STAG2 (28% vs. 8%; p<0.001). Normal karyotype was more frequent in both isoforms (IDH1 58%, IDH2 65% vs. 42%; p<0.02). Consensus clustering of IDH1 patients identified an SRSF2-enriched, normal karyotype subgroup (n=19; mOS not reached vs 38.5 months for WT; p=0.008) and an abnormal karyotype subgroup (n=27; mOS 44.0 months; p=0.30 vs. WT). IDH2 clustering revealed two molecularly distinct subgroups: SRSF2/ASXL1/STAG2-driven (n=44) and SF3B1/U2AF1/DNMT3A-driven (n=38), but OS did not differ between clusters (p=0.47).

Median OS was 57.6 months for IDH1, 40.7 months for IDH2, and 38.5 months for WT. The mOS of IDH1 was better than WT (p=0.021), with no difference between IDH2 and WT (p=0.428). In multivariable analysis, IDH1 was independently associated with favorable OS (HR 0.47; 95% CI 0.28–0.77; p=0.003), while IDH2 remained neutral (HR 0.85; 95% CI 0.62–1.17; p=0.32). This IDH1 advantage was consistent across risk strata: lower-risk mOS 78.2 vs 59.7 months (p=0.035); higher-risk mOS 35.7 vs 20.3 months (p=0.10; MVA HR 0.41; p=0.014).

In a time-dependent Cox model, the IDH1 advantage persisted (HR 0.48; 95% CI 0.25–0.83; p=0.008). IDH1 patients had a higher cumulative incidence of AML at 36 months (26.6% vs 20.0%; p=0.111) but significantly lower death without AML (15.2% vs. 32.0%; p=0.004). IDH2 showed favorable OS only in higher-risk disease (mOS 36.8 vs. 20.3 months; p=0.026). Among IDH-mutant patients, venetoclax exposure as a time-dependent covariate improved OS, controlling for age, ECOG, and stratified by IPSS-R risk (HR 0.33, 95% CI, 0.14–0.75; p=0.009).

 

Conclusions

In one of the largest clinical studies of IDH-mutated MDS in the modern treatment era, IDH1 mutations are independently associated with favorable survival in MDS, challenging the adverse prognostic classification assigned by prior studies and current scoring systems. IDH1 and IDH2 have divergent prognostic impacts, distinct co-mutation landscapes, and molecularly defined subgroups. The availability of novel therapies may contribute to improved prognoses. These findings have direct implications for risk stratification and therapeutic decision-making in IDH-mutant MDS.

Ian Bouligny, M.D.: No relevant conflicts of interest to declare.